Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice
Open Access
- 15 August 2017
- journal article
- research article
- Published by Springer Nature in BMC Immunology
- Vol. 18 (1) , 1-11
Abstract
Cancer therapeutic vaccine induced cytotoxic T cell (CTL) responses are pivotal for the killing of tumour cells. Blocking interleukin 10 (IL-10) signalling at the time of immunization increases vaccine induced CTL responses and improves prevention of tumour growth in animal models compared to immunization without an IL-10 signalling blockade. Therefore, this immunization strategy may have potential to curtail cancer in a clinical setting. However, IL-10 deficiency leads to autoimmune disease in the gut. Blocking IL-10 at the time of immunization may result in unwanted side effects, especially immune-pathological diseases in the intestine. We investigated whether blocking IL-10 at the time of immunization results in intestinal inflammation responses in a mouse TC-1 tumour model and in a NOD autoimmune disease prone mouse model. We now show that blocking IL-10 at the time of immunization increases IL-10 production by CD4+ T cells in the spleen and draining lymph nodes, and does not result in blood cell infiltration to the intestines leading to intestinal pathological changes. Moreover, immunization with papillomavirus like particles combined with simultaneously blocking IL-10 signalling does not increase the incidence of autoimmune disease in Non-obese diabetic (NOD) mice. Our results indicate that immunization with an IL-10 inhibitor may facilitate the generation of safe, effective therapeutic vaccines against chronic viral infection and cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81472451)
- Foshan Municipal Government (2012AA100461; 2015AG1003)
- Guangdong Provincial Department of Science and Technology (2016A020213001; 2012B03180003)
This publication has 51 references indexed in Scilit:
- IL-17 Mediates Immunopathology in the Absence of IL-10 Following Leishmania major InfectionPLOS Pathogens, 2013
- IL-10 Mediated Regulation of Liver Inflammation during Acute Murine Cytomegalovirus InfectionPLOS ONE, 2012
- A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesionsCancer Immunology, Immunotherapy, 2012
- Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerCurrent Opinion in Virology, 2011
- Development of therapeutic HPV vaccinesThe Lancet Oncology, 2009
- The Therapeutic Vaccine: Is it Feasible?Archives of Medical Research, 2009
- Enhanced Antibody Responses Elicited by a CpG Adjuvant Do Not Improve the Protective Effect of an Aldrithiol-2-Inactivated Simian Immunodeficiency Virus Therapeutic AIDS VaccineClinical and Vaccine Immunology, 2009
- IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infectionJournal of Experimental Medicine, 2008
- Conventional T-bet+Foxp3− Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infectionJournal of Experimental Medicine, 2007
- CD4+CD25−Foxp3− Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasisJournal of Experimental Medicine, 2007